Skip to content
Screener

ADMA Biologics ADMA Q1 2025 earnings

Reported May 7, 2025 · After market close

Revenue$114.8MMiss by $7.0M
EPS$0.14Miss by $0.02
Revenue estimate$121.8M
EPS estimate$0.16

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$138.1M
EPS estimate$0.19

Financials

Q1 2025

Income statement

See full
Revenue$114.8M+40.2%
Gross profit$61.1M+56.2%
Operating income$34.9M+59.9%
Net income$26.9M+51.1%
EPS (diluted)$0.11+37.5%

Balance sheet

See full
Cash & equivalents$71.6M+58.0%
Total debt$9.5M-10.3%
Total equity$373.4M+143%
Total assets$510.6M+45.5%

Cash flow

See full
Operating cash flow-$19.7M-787%
CapEx$4.7M+100%
Free cash flow-$24.4M-434%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$4.71B+213%
Enterprise value$4.65B+216%
P/E22.8×—
P/S10.3×+4.9×

Profitability

See full
Gross margin52.6%+13.2pp
Operating margin33.1%+17.5pp
Net margin45%+43.8pp
FCF margin19.7%+14.0pp

Returns & leverage

See full
Return on equity78.5%+76.2pp
Debt / equity0×0.0×
Current ratio6.6×+1.4×

Segments

By product

See full
ASCENIV$76.3M+27.4%
BIVIGAM$33.5M—
Intermediates And Other$3.9M—

By segment

See full
ADMA Bio Manufacturing$113.7M+41.9%
Plasma Collection Centers$1.1M-39.2%

By geography

See full
US$110.7M—

FAQ

When did ADMA Biologics report Q1 2025 earnings?
ADMA Biologics (ADMA) reported Q1 2025 earnings on May 7, 2025 after market close.
What were ADMA Biologics's Q1 2025 revenue and EPS?
ADMA Biologics reported revenue of $114.8M and eps of $0.14 for Q1 2025.
Did ADMA Biologics beat estimates in Q1 2025?
Revenue missed the consensus estimate of $121.8M by $7.0M. EPS missed the consensus estimate of $0.16 by $0.02.
How did ADMA Biologics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 40.2% from $81.9M a year earlier and eps grew 75.0% from $0.08.
Where can I find ADMA Biologics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001140361-25-017704) and the 10-Q periodic report (0001140361-25-017747) directly on SEC EDGAR. The filing index links above go to sec.gov.